Seeking Alpha

KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ...

KEYTRUDA and KEYTRUDA QLEX are the first and only PD-1 inhibitors approved for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma with PD-L1+ tumors ...
Medscape

Survival Benefit With Pembro in TNBC, but Only for Subgroup

New longer-term results show a survival benefit from adding the immune checkpoint inhibitor pembrolizumab (Keytruda) to first-line chemotherapy for women with metastatic triple-negative breast cancer ...
Healio

Pembrolizumab regimens snag FDA nod for PD-L1-positive, platinum-resistant ovarian cancers

Please provide your email address to receive an email when new articles are posted on . The FDA approved pembrolizumab regimens for patients with PD-L1 positive, platinum-resistant ovarian cancers. A ...
The American Journal of Managed Care

FDA Approves Use of Subcutaneous Pembrolizumab for NSCLC, Most Solid Tumors

FDA approved pembrolizumab and berahyaluronidase alfa-pmph for patients aged 12 and older with solid tumors. Study MK-3475A-D77 showed a 45% ORR in subcutaneous administration for treatment-naïve ...